Abstract
Introduction:
Percutaneous nephrolithotomy (PCNL) is the gold standard treatment for upper tract stone burdens greater than 2 cm. Metabolic syndrome (MetS) is a constellation of conditions (diabetes mellitus, hypertension, dyslipidemia, and obesity) and is a risk factor for nephrolithiasis. Our objective was to investigate adverse cardiovascular outcomes of PCNL in patients with comorbid MetS diagnoses.
Materials and Methods:
Data from the Healthcare Cost and Utilization Project State Inpatient Database for Florida and California were used to identify PCNL patients (ICD9: 55.03, 55.04) between 2007 and 2011. Patients were categorized having 0, 1–2, or 3–4 components of MetS. Postoperative myocardial infarction (MI) and inhospital mortality rate outcomes were identified. Multivariate logistic regression was used to control for patient characteristics (age, race, and primary insurance provider) and medical comorbidities.
Results:
PCNL was performed on 39,868 patients, of whom 17,932 (45.0%) had no MetS conditions, 19,268 (48.3%) had 1–2 MetS conditions, and 2668 (6.7%) had 3–4 MetS conditions. With increasing MetS conditions, patients had increased incidence of postoperative MI (0: 0.6%; 1–2: 1.0%; 3–4: 1.8%, p < 0.001). On multivariate analysis, the presence of 3–4 MetS comorbidities increased the odds of a postoperative MI (1–2: odds ratio [OR] 1.2, 95% confidence interval [CI] 0.94–1.53, p = 0.147; 3–4: OR 2.2, 95% CI 1.54–3.15, p < 0.001).
Conclusions:
MetS patients have an increased risk of MI following PCNL given their pre-existing comorbidities. Routine preoperative cardiac testing may benefit this population before PCNL.
Get full access to this article
View all access options for this article.